Tenascin-C fragments are endogenous inducers of cartilage matrix degradation by Sofat, N et al.
ORIGINAL ARTICLE
Tenascin-C fragments are endogenous inducers of cartilage
matrix degradation
Nidhi Sofat • Saralili Dipa Robertson •
Monika Hermansson • Jonathan Jones •
Philip Mitchell • Robin Wait
Received: 8 January 2011 / Accepted: 10 August 2011 / Published online: 27 August 2011
 The Author(s) 2011. This article is published with open access at Springerlink.com
Abstract Cartilage destruction is a hallmark of osteoar-
thritis (OA) and is characterized by increased protease
activity resulting in the degradation of critical extracellular
matrix (ECM) proteins essential for maintaining cartilage
integrity. Tenascin-C (TN-C) is an ECM glycoprotein, and
its expression is upregulated in OA cartilage. We aimed to
investigate the presence of TN-C fragments in arthritic
cartilage and establish whether they promote cartilage
degradation. Expression of TN-C and its fragments was
evaluated in cartilage from subjects undergoing joint
replacement surgery for OA and RA compared with normal
subjects by western blotting. The localization of TN-C in
arthritic cartilage was also established by immunohisto-
chemistry. Recombinant TN-C fragments were then tested
to evaluate which regions of TN-C are responsible for
cartilage-degrading activity in an ex vivo cartilage explant
assay measuring glycosaminoglycan (GAG) release, agg-
recanase and matrix metalloproteinase (MMP) activity. We
found that specific TN-C fragments are highly upregulated
in arthritic cartilage. Recombinant TN-C fragments con-
taining the same regions as those identified from OA car-
tilage mediate cartilage degradation by the induction of
aggrecanase activity. TN-C fragments mapping to the
EGF-L and FN type III domains 3–8 of TN-C had the
highest levels of aggrecan-degrading ability that was not
observed either with full-length TN-C or with other
domains of TN-C. TN-C fragments represent a novel
mechanism for cartilage degradation in arthritis and may
present new therapeutic targets for the inhibition of carti-
lage degradation.
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Introduction
Osteoarthritis (OA) is the most common joint disorder
affecting increasing numbers of our ageing populations [1,
2]. Factors contributing to tissue damage include cytokine
release, superoxide production and protease activation
ultimately leading to loss of joint function [3–6]. Current
treatments are largely focused around control of pain and
maintenance of function, since there are no effective dis-
ease-modifying treatments for OA [7]. There is therefore
an unmet need to gain a deeper understanding of the
mechanisms underlying joint destruction in OA.
A number of factors influence ongoing cartilage damage
in OA, including injurious mechanical compression of car-
tilage that alters gene transcription of degradative enzymes
including MMPs and aggrecanases (ADAMTSs) [8, 9]. Such
proteases degrade the key extracellular matrix (ECM)
components of cartilage including type II collagen and
aggrecan [10, 11]. Several studies have shown increased
production of ECM molecules during the early stages of OA
[12–14]. Type II collagen, cartilage oligomeric matrix pro-
tein (COMP), fibronectin, fibromodulin and tenascin-C are
among the ECM proteins that are altered in OA cartilage both
at the messenger RNA and protein level. As ongoing prote-
ase-mediated cartilage destruction ensues, fragments of
ECM proteins are generated, which accumulate during
ongoing disease progression.
Recent reports suggest that specific ECM proteins
become endogenous catabolic factors potentiating further
joint damage in OA. Activation of pro-inflammatory
pathways by such ECM proteins has led to their description
as damage-associated molecular patterns (DAMPs). Sev-
eral groups have shown that fragments of ECM proteins
acquire novel proteolytic activity upon fragmentation that
was hitherto absent in the full-length molecule. For
example, a fragment of type II collagen localizing to the
N-terminus of the molecule upregulates mRNA and protein
levels of MMP-2, MMP-3, MMP-9 and MMP-13 in bovine
chondrocytes and explants [15]. Other ECM molecules
showing distinct activity upon fragmentation include fi-
bromodulin, hyaluronan and fibronectin [16–18]. However,
it is unclear whether these are the only protein fragments
responsible for further cartilage destruction. Tenascin-C
(TN-C) is an ECM glycoprotein associated with tissue
injury and repair. TN-C is a hexameric protein of 1.5
million Da comprising an assembly domain, epidermal
growth factor-like repeats (EGF-L), fibronectin type III
repeats (TNIII) and a fibrinogen-like globe (FBG) [19].
Little TN-C is expressed in normal human joints, but
expression is increased in cartilage [20, 21], synovial tissue
[22, 23] and synovial fluid [24] in OA and RA. TN-C
potentiates chronic inflammation in RA by the upregulation
of pro-inflammatory cytokines, and this effect is not
observed in TN-C knockout mice [25]. In contrast, in a
murine model of OA, TN-C knockout mice showed evi-
dence of delayed healing and repair [26]. The increased
levels of TN-C reported in OA tissue and the homology of
TN-C domains to other known DAMPs in cartilage
prompted us to examine whether TN-C fragments exist in
arthritic cartilage and whether TN-C fragments possess
novel cartilage-degrading ability.
Materials and methods
Preparation of human cartilage extracts
Human cartilage samples from patients undergoing joint
replacement surgery for OA of the knee/hip or normal car-
tilage obtained from patients undergoing amputations for
trauma were obtained with full Ethics Approval (REC
reference number: 09/H0806/45) from St George’s and
Heatherwood Hospitals NHS Trust. All participants donated
tissue with full informed consent. All reagents were obtained
from Sigma-Aldrich unless otherwise stated. Human carti-
lage was washed three times in sterile PBS, and a total of
0.1 g was collected per subject. The cartilage was further
dissected in 1 ml of 2 9 reducing sample buffer containing
0.2 g SDS, 5 ml upper gel buffer consisting of 84 mM
ammediol, 62 mM HCl and 0.02% sodium azide, 1 ml bro-
mophenol blue, 4 ml glycerol and 880 ll of 0.5 M EDTA
(pH 8.0) to a final volume of 11 ml. The dissected cartilage
and sample buffer were carefully transferred to a 1.5-ml
Eppendorf tube and boiled at 100C for 10 min. The samples
were stored at -20C until further use.
Immunohistochemistry of human cartilage
Fresh cartilage for sectioning was obtained at the time of
joint surgery from subjects and immediately fixed in 4%
paraformaldehyde in 0.1% phosphate-buffered saline (PBS;
pH 7.4) and then sectioned using a cryostat into 7 micron
slices onto polylysine-coated glass slides (VWR, Leuven,
Belgium). To block endogenous peroxidase activity, 3%
H2O2 was applied in the dark for 15 min. Sections were then
blocked with 2% goat serum for 30 min. Following this,
sections were incubated with an anti-TN-C monoclonal
antibody raised against the N-terminal heptad region of TN-
C (MAB 1908, Millipore, Watford, UK) at 1:1,000 for 1 h at
room temperature, followed by incubation with Dako REAL
EnVision detection system/HRP for rabbit/mouse secondary
antibodies for 30 min (Dako, Denmark). For control exper-
iments, a mouse IgG primary antibody (SC-2025) (Santa
Cruz, Heidelburg, Germany) was used. Signal was
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developed with the Dako REAL DAB ? chromogen sub-
strate system according to the manufacturers’ instructions.
Slides were counterstained with haematoxylin and mounted
with Histomount (National Diagnostics, Atlanta, USA). All
slides were viewed with a Zeiss AXIOPLAN 2 light
microscope running on Axiovision system 4.7.
SDS–PAGE and western blotting
Proteins were resolved by SDS/PAGE with reduction using
the ammediol/glycine/HCl buffer system of Wyckoff et al.
[27] for the Tris–glycine buffer method according to Lae-
mmli [28]. Gels were typically run for 60 min at 200 V.
Staining with Coomassie Brilliant Blue R-250 and silver
was performed as previously described [29, 30]. For wes-
tern blotting, gels were electrotransferred onto a PVDF
membrane at 25 V (constant voltage) for 240 min in
200 ml transfer buffer containing 20% v/v methanol, 7.2 g
glycine and 1.512 g Tris base. Five percentage BSA was
used for blocking, for 30 min following which the primary
anti-TN-C antibody in 1% BSA/TBS for 1 h (dilution
1:1,000). The membrane was washed three times with
TBS/0.05% Tween. After washing, a 1:5,000 dilution of an
AP-linked secondary antibody (Promega, Southampton,
UK) in 1% BSA/TBS was added and incubated for 1 h.
Membranes were washed three times in TBS/0.05% Tween
and incubated with AP substrate for development for up to
30 min.
Tenascin-C and recombinant TN-C proteins
Full-length tenascin-C (Millipore, Watford, UK) was dia-
lysed into TBS buffer (50 mM Tris–HCl, 150 mM NaCl,
pH 7.5) before use in cartilage explant cultures. Recom-
binant TN-C domains were produced as previously
described [25]. The Limulus amoebocyte lysate (LAL)
assay (Cambrex, Wiesbaden, Germany) was used to test the
amount of LPS in all purified and recombinant TN-C
proteins as previously described [25]. A standard curve was
performed for each experiment using E.coli-derived LPS
that was provided in the kit. Detection levels for purified
proteins were undetectable in the 1–100 pg/ml range,
which is well below the levels required to stimulate carti-
lage degradation.
Measurement of glycosaminoglycan release,
aggrecanase and MMP activity
Fresh porcine metacarpophalangeal joints of 3- to 9-month-
old pigs (Turners’, Hampshire, UK) or human tissue were
obtained with full Ethical Approval (REC reference number:
09/H0806/45) and dissected into pieces 3 mm 9 2–3 mm
wide (about 10 mg) as we have previously described [31,
33]. After dissection, cartilage was rested for 48 h at 37C
under 5% CO2 in DMEM containing 5% foetal calf serum,
penicillin/streptomycin (100 units/ml), amphotericin B
(100 units/ml) and 10 mM HEPES. Each cartilage piece was
placed in one well of a round bottom 96-well plate with
200 ll of serum-free medium with full-length TN-C,
recombinant TN-C fragments, IL-1a (a gift from Prof J
Saklatvala, Imperial College London) as a positive control.
Each treatment was performed in triplicate. After 48 h,
media and cartilage were harvested and stored at -20C until
use. Each experiment was performed at least 3 times on
separate porcine trotters.
The total GAG released into media by cartilage was
measured using a modification of the DMMB assay [32]. A
volume of 250 ll of the DMMB assay reagent (16 mg/ml
DMMB, 41 mM sodium chloride, 40 mM glycine, 9.5 mM
HCl) was added to 2.5 ll of culture medium in a 96-well
plate, and then the absorbance was read immediately at
540 nm. Each sample was assayed in duplicate. The optical
density from the experimental samples was converted into
lg of chondroitin from the standard curve.
Aggrecanase and MMP activity in the conditioned
medium of treated cartilage was determined using neoepi-
tope assays as previously described [31, 33]. Aggrecanase
and MMP-specific neoepitope antibodies anti-ARGSV
(BC-3) and anti-FFGVG (BC-14), respectively, were kindly
provided by Professor Bruce Caterson and Dr Clare Hughes
(University of Wales, Cardiff).
Statistics
The GAG release assay in cartilage explants was evaluated
using Graphpad Prism software (San Diego, California).
Mean values were calculated for each treatment in tripli-
cate and expressed as mean ± standard error of mean.
Significance was analysed with two-tailed Student’s t tests
and defined as P \ 0.05.
Results
Full-length TN-C and TN-C fragments are upregulated
in arthritic cartilage
We analysed the expression of full-length TN-C and its
fragments in normal human and arthritic cartilage. TN-C
protein was detected in its full-length form at *170 and
*240 kDa, representing the known short and long forms
of TN-C (Fig. 1a). In contrast to normal cartilage, levels of
full-length TN-C expression were highly upregulated in
cartilage extracts from OA and RA cartilage (lanes 4–12,
Fig. 1a). Two additional forms of TN-C were increased in
OA and RA samples and detected at *100 and*150 kDa.
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The results represent true comparisons of equal amounts of
protein since equivalent gels as those used for western
blotting were stained with Coomassie Brilliant Blue and
showed equal protein loading in the specimens (Fig. 1b).
These combined results show that increased expression of
full-length TN-C and specific TN-C fragments is found in
human arthritic cartilage compared with normal tissue.
Since the anti-TN-C antibody we used recognizes the
N-terminal attachment region of TN-C, we could predict the
composition of the TN-C fragments detected in our studies
of human arthritic cartilage (Fig. 2). Results show that since
the main TN-C fragments we found in cartilage are of
molecular weight 100 and 150 kDa, the fragments detected
are most likely to comprise of TN-C fragments mapping to
the TA ? EGF-L ? FN type III repeats 1–3 (theoretical
molecular mass 97 kDa) and the TA ? EGF-L ? FN type
III repeats 1–8 (theoretical molecular mass 147 kDa).
We next confirmed TN-C localization in arthritic carti-
lage by immunohistochemistry. Our results for TN-C
staining in OA cartilage show that TN-C expression was
predominantly focused around the superficial and midzones
of arthritic human cartilage (Fig. 3). The highest intensity
of TN-C staining was detected primarily within chondro-
cytes and the pericellular matrix of OA cartilage. An iso-
type control IgG antibody did not show any positive
staining, showing that the staining observed in OA carti-
lage was specific for TN-C.
Recombinant TN-C fragments induce
glycosaminoglycan release and aggrecanase activity
in cartilage
Since we detected TN-C fragments in arthritic cartilage, we
then evaluated the potential for TN-C fragments to induce
cartilage degradation. Recombinant fragments comprising
Fig. 1 Western blot analysis of cartilage extracts from patients using
an anti-TN-C antibody. A total of 1 lg protein was run per well and
membranes developed with alkaline phosphatase (AP) substrate for
1 min each. Sample identification: 1 29 (F), lower leg, amputation; 2
17 (F), lower limb, osteosarcoma; 3 45 (M), lower limb, amputation;
4 72 (M), hip OA; 5 68 (M), hip OA; 6 72 (M), knee OA; 7 75 (F),
knee OA; 8 71 (M), hip OA; 9 70 (F), knee OA; 10 66 (F), knee OA;
11 45 (M), hip, RA; 12 69 (F), hip, RA. b Equivalent samples used as
in (a) with 1 lg protein per well stained with Coomassie Brilliant
Blue
Fig. 2 Domain composition of
TN-C fragments identified from
arthritic cartilage. Human TN-C
has a modular structure with
repeating units: the TA
attachment (heptad) domain at
the N-terminus, 14.5 EGF-L
repeats, 8–17 FN type III
repeats (conserved type III
repeats numbered 1–8 are
present in all isoforms with
splice variants labelled by their
designated letter format) and a
fibrinogen (FBG) globe at the
C-terminus. The table shows the
composition of TN-C fragments
isolated from arthritic cartilage
in our study
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the TN-C attachment (TA) domain, the EGF-like (EGF-L)
repeats, TN1-5, TN1-3, TN3-5, TN5-7, TN6-8 and the
fibrinogen globe (FBG) were cultured with normal porcine
articular cartilage (Fig. 4). Experiments were initially
conducted at 1 lM TN-C fragments since this is the active
concentration of other ECM DAMPs such as fibronectin
fragments that share domain homology with TN-C. The
TN-C fragments with greatest statistically significant
GAG-releasing activity in porcine articular cartilage were
EGF-L, TN3-5, TN5-7, TN6-8 as measured by the DMMB
assay (Fig. 4). The TN-C attachment domain, TN1-3 and
the FBG globe did not have statistically significant levels
of GAG release. In addition, full-length TN-C also showed
no evidence of cartilage degradation. We analysed which
enzymes were mediating the GAG release observed by the
active TN-C fragments. Figure 4 shows that aggrecanase
neoepitope activity was induced by TN-C fragments TN6-
8, TN5-7, EGF-like repeats and TN3-5 using the anti-
ARGSV antibody that was similar to levels induced by IL-
1a. These TN-C fragments showed significant aggrecanase
activity compared with medium alone and full-length TN-
C. The other TN-C fragments showed no significant
increase in aggrecanase activity compared with negative
controls. When conditioned medium was tested for cleav-
age by MMPs using the MMP-cleavage-specific antibody
anti-FFGVG, no neoepitope signal was detected in TN-C
fragment-treated explants, although cleavage was observed
in IL-1a-treated conditioned medium.
We then tested the dose–response effect of active
recombinant TN-C fragments in normal porcine and human
articular cartilage. We found that the active fragments
maintained their GAG-releasing activity over the micro-
molar range, with the most significant activity observed at
0.1 and 1 lM concentrations (Fig. 5a). The GAG release
assay showed that the highest levels of cartilage degrada-
tion were induced by the EGF-L repeats and TN6-8 in the
0.01–1 lM range. In experiments with normal human
articular cartilage (obtained from a 69-year-old subject
who underwent joint replacement for a fractured neck of
femur), we found that the same TN-C fragments that were
active in porcine articular cartilage also had GAG-releasing
activity in the micromolar range in normal cartilage
(Fig. 5b). It was also noted that differences in total GAG
release between experiments in Figs. 4 and 5 were found,
which are most likely due to natural variation in glycos-
aminoglycan release between different cartilage explants.
Discussion
In this study, we have shown that two main forms of
fragmented TN-C of 100 kDa and 150 kDa are detectable
in arthritic cartilage but not in normal subjects. The TN-C
fragments we have detected map to the EGF-L and FN type
III 3–8 domains in arthritic human cartilage. Recombinant
TN-C fragments comprising the same domains induce
GAG release and aggrecanase activity in cartilage in a
dose-dependent manner. Although increased TN-C
expression has previously been described in arthritic car-
tilage [20, 21, 34], our study is the first to describe and
characterize TN-C fragments in cartilage. Zhen et al. [35]
recently showed that human cartilage subjected to diges-
tion with ADAMTS-5 cleaves TN-C peptides that map to
the N-terminal TA domain when digested cartilage was
analysed by mass spectrometry. It is therefore plausible
that the generation of TN-C fragments by proteases such as
Fig. 3 Distribution of TN-C in human OA cartilage. a–d are images
from 2 OA subjects stained with anti-TN-C antibody. e–h are the
same OA subjects stained with an isotype control IgG mouse
antibody. Zones of cartilage are delineated using the following
abbreviations—S superficial, M midzone, D deep zone. Bars indicate
section size of 10 lM or 50 lM
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ADAMTS-5 generates TN-C fragments which then stim-
ulate a positive feedback loop of further cartilage matrix
degradation mediated by protease activation including
aggrecanases as found in our study.
Work conducted in other tissues has shown that leg ulcer
exudates have high levels of TN-C fragments [36] and the
EGF-L repeats are increased in blood vessels of subjects
undergoing carotid endarterectomy [37]. Specific TN-C
fragments have distinct functions: the EGF-L domains
influence neuronal migration in development [38, 39] and
induce apoptosis in smooth muscle cells [36]. The FN III
domains of TN-C are susceptible to proteolytic cleavage [40]
and interact with ligands including integrins [41], heparin
binding [42] and binding to other ECM molecules including
fibronectin [43]. Whereas previous work has shown that full-
length TN-C is involved in wound repair in OA [26, 34], our
Fig. 4 TN-C fragments induce
cartilage degradation in normal
articular cartilage.
a Recombinant TN-C fragments
used for cartilage stimulation
were run on SDS–PAGE. All
proteins were loaded at 1 lg
each and stained with silver.
b TN-C fragments at 1 lM were
used to stimulate porcine
cartilage explants for 2 days.
The culture medium was
harvested and tested for the
presence of GAG using the
DMMB dye assay (n = 3). c,
d Equal volumes of conditioned
media (50 ll) from the
experiment shown in b were
deglycosylated and western
blots performed for
aggrecanase-cleaved
neoepitopes using the BC-3
antibody (c) and the BC-14
antibody (d). Loading controls
were medium alone, c, used as a
negative control and IL-1a,
which served as a positive
control
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work has shown that when TN-C is cleaved to generate
fragmented forms, such TN-C fragments acquire novel
proteolytic activity that mediates catabolic pathways in
articular cartilage. There are therefore differences between
the full-length and fragmented forms of TN-C, which
mediate anabolic and catabolic pathways, respectively, in
OA models.
Based on our findings and those of other groups, we pro-
pose a scheme whereby a balance between anabolic effects
and catabolic effects mediated by TN-C fragments and other
ECM protein fragments occur in the OA joint (Fig. 6). Future
work will be required to establish pathways of activation
induced by the active TN-C fragments we have identified. It is
possible that TN-C fragments such as those we have identified
engage with existing receptors in the OA joint, including
syndecans [44], integrins [45] or toll-like receptors [46].
Alternatively, it is possible that specific forms of TN-C may
inhibit aggrecanase activity, as described in the case of the
C-terminal region of fibronectin with ADAMTS-4 [47].
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